Early antibody treatment, inflammation, and risk of post-COVID conditions

By sjmartinez • September 20, 2023

Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, Habtehyimer F, Shade D, Ruff J, Ram M, Laeyendecker O, Fernandez RE, Patel EU, Baker OR, Shoham S, Cachay ER, Currier JS, Gerber JM, Meisenberg B, Forthal DN, Hammitt LL, Huaman MA, Levine A, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Anjan S, Gniadek T, Kassaye S, Blair JE, Lane K, McBee NA, Gawad AL, Das P, Klein SL, Pekosz A, Bloch EM, Hanley D, Casadevall A, Tobian AAR, Sullivan DJ; CSSC-004 Consortium. Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio. 2023 Sep 19:e0061823. doi: 10.1128/mbio.00618-23. Epub ahead of print. PMID: 37724870.

Tags: chemokines, covid-19, COVID-19 serotherapy, Cytokines, Infectious Diseases, Interleukin-6, post-acute sequelae of COVID (PASC), post-COVID condition (PCC), Publications

Ceftriaxone resistance in Neisseria gonorrhoeae associated with the penA-60.001 allele in Hanoi, Viet Nam

Adamson PC, Hieu VN, Nhung PH, Whiley DM, Chau TM. Ceftriaxone resistance in Neisseria gonorrhoeae associated with the penA-60.001 allele in Hanoi, Viet Nam. Lancet[...]

Hyphal Als proteins act as CR3 ligands to promote immune responses against Candida albicans

Zhou T, Solis NV, Marshall M, Yao Q, Garleb R, Yang M, Pearlman E, Filler SG, Liu H. Hyphal Als proteins act as CR3 ligands[...]

The gut microbiome in alcohol use disorder and alcohol-associated liver disease: A systematic review of clinical studies

Grodin EN, Burnette EM, Rodriguez C, Fulcher JA, Ray LA. The gut microbiome in alcohol use disorder and alcohol-associated liver disease: A systematic review of[...]